Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013)
Akebia Therapeutics (AKBA) reported Preferred Stock Liabilities of $157.8 million for Q4 2013.
Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013) Analysis & Trends
Akebia Therapeutics (AKBA) has 1 years of Preferred Stock Liabilities data on file, last reported at $157.8 million in Q4 2013.
- Preferred Stock Liabilities for Q4 2013 came in at $157.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2013 was $157.8 million (changed N/A YoY), and the FY2013 annual result was $157.8 million, up 325.5% from the prior year.
- Preferred Stock Liabilities steadied at $157.8 million in Q4 2013 per AKBA's latest filing.
- Over five years, Preferred Stock Liabilities peaked at $157.8 million in Q4 2013 and troughed at $157.8 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 157.83 Mn |